Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24188
Abstract: A targeted therapy is recommended in case of ERBB2 alteration for breast and gastric carcinomas, but miscellaneous other tumor types are ERBB2-altered at low prevalence. Broadening the administration of HER2 inhibitors across tumor types and… read more here.
Keywords: tumor types; erbb2 amplifications; histology; her2 inhibitors ... See more keywords